Fayad Al-Haimus։ HI-PEITHO Shows Reduced PE Complications Without Increased Bleeding
Fayad Al-Haimus, Adult Thrombosis Fellow at McMaster University, shared a post on LinkedIn about a recent article by Kenneth Rosenfield et al. published in The New England Journal of Medicine (NEJM):
”The HI-PEITHO trial landed in NEJM Group last week. Worth a read if you manage PE.
The background: intermediate-high-risk PE has always been a difficult call.
Anticoagulation alone felt insufficient for the sickest patients, but systemic thrombolysis carried some bleeding risk as well (approximately 2% intracranial hemorrhage in PEITHO-1) to use routinely.
HI-PEITHO tested low-dose alteplase delivered via catheter directly into the pulmonary artery: 544 patients, 59 sites across the US and Europe.
At 7 days, the primary composite endpoint (PE-related death, cardiopulmonary decompensation, or recurrence) occurred in 4.0% of the catheter-directed thrombolysis group versus 10.3% on anticoagulation alone, roughly a 60% relative risk reduction.
Major bleeding was similar between groups.
A few things worth keeping in mind before updating practice:
- No mortality benefit demonstrated; the signal is in short-term decompensation.
- It remains unclear whether the ultrasound component adds anything over low-dose catheter alteplase alone.
The trial gives the field something it has been lacking; a reasonably powered RCT with a clear signal in a population that has been genuinely hard to manage.”
Title: Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism
Authors: Kenneth Rosenfield, Frederikus A. Klok, Gregory Piazza, Andrew S.P. Sharp, Fionnuala Ní Áinle, Michael R. Jaff, Stefano Barco, Samuel Z. Goldhaber, Nils Kucher, Irene M. Lang, Irene Schmidtmann, Keith M. Sterling, Aleksander Araszkiewicz, Vishal Arora, Rafael Cires-Drouet, John Coghlan, Lukas Hobohm, Wulf D. Ito, Kurt Jacobson, Christoph Kaiser, Grzegorz Kopec, Kristin Marx, Samuel McElwee, Nicolas Meneveau, Peter Monteleone, Jose M. Montero-Cabezas, Christoph B. Olivier, John Park, Marek Roik, Rahul Sakhuja, Andi Tego, Markus Theurl, Gautam Visveswaran, Jan Albert Vos, Michael N. Young, Federico M. Asch, Stavros V. Konstantinides

Stay updated on all scientific advances with Hemostasis Today.
-
Sep 6, 2026, 14:50Mohamed F Doheim: Unraveling the Symphony of Stroke Management
-
Sep 6, 2026, 14:47Ahmed Bennis: E-Cigarette Use and Early Cardiovascular Risk in Young Adults
-
Sep 6, 2026, 14:46William Wallace: Iron Deficiency Can be Present Before Hemoglobin Falls and Before Anemia Appears
-
Sep 6, 2026, 14:15Listening to One Another Drives Innovation and Better Therapies in Hemophilia Care – Global Hemophilia Report
-
Sep 6, 2026, 14:12Filippo Crea: Exploring the Role of PAR4 in Platelet Hyperactivation in Hypertension
-
Sep 6, 2026, 14:10PALOP Coalition in Action: Practical Haemophilia Training in Angola – NNHF
-
Sep 6, 2026, 14:07Webinar on the Global Prevalence and Ethnic Diversity of von Willebrand Disease – EHC
-
Sep 6, 2026, 14:04Fatima Jamali: Advancements and Real-World Insights in Cell and Gene Therapy at MENA Rare Diseases 2026
-
Sep 6, 2026, 13:33Antoine Francis: Albumin – The Donor Patient Equation